| abstract |
Compounds of general formula (I) wherein: R1 is H or optionally joined with R2 to form a fused ring selected from the group consisting of five to ten membered aryl, heteroaryl or heterocyclyl rings, R?2 and R3¿ are independently H, HET, aryl, C¿1-12? aliphatic, CN, NO2, halogen, R?10, -OR10, -SR10¿, -S(O)R10, -SO2R?10, -NR10R11, -NR11R12, -NR12COR11, -NR12CO¿2R?11, -NR12CONR11R12, -N012SO¿2R?11, -NR12C(NR12)NHR11, -COR11, -CO¿2R?11, -CONR12R11, -SO¿2NR12R11, -OCONR?12R11, C(NR12)NR12R11, R6 and R7¿ are independently halogen, CN, NO¿2?, -CONR?10R11, -SO¿2NR?10R11, -NR10R11¿, or -OR11, where R?10 and R11¿ are as defined below; R8 is OH, NHSO¿2R?12 or NHCOCF¿3?; and their use in therapy, especially in the treatment of disorders mediated by cRaf1 kinase. |